Inventor · disambiguated record
Heinrich Röder
Also filed as: RODER HEINRICH · ROEDER HEINRICH · RÖDER HEINRICH
43 granted patents·14 pending applications·448 citations·filing 2001–2024
98Inventor score
Files withBIODESIX INC40ROEDER HEINRICH6IOVANCE BIOTHERAPEUTICS INC2RÖDER HEINRICH2DATAPHYSICS RES INC1
Top patents by PatentIndex Score
57 records- 0198US7736905B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2006·Granted Jun 15, 2010·72 cites·18 claims
- 0296US8718996B2Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2013·Granted May 6, 2014·19 cites·10 claims
- 0395US10489550B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2017·Granted Nov 26, 2019·13 cites·7 claims
- 0495US7906342B2Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesBIODESIX INC·Filed 2009·Granted Mar 15, 2011·23 cites·3 claims
- 0595US7879620B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2010·Granted Feb 1, 2011·24 cites·8 claims
- 0695US7858389B2Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·30 cites·4 claims
- 0793US10007766B2Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2016·Granted Jun 26, 2018·9 cites·8 claims
- 0893US9779204B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2015·Granted Oct 3, 2017·7 cites·6 claims
- 0993US9563744B1Method of predicting development and severity of graft-versus-host diseaseBIODESIX INC·Filed 2015·Granted Feb 7, 2017·9 cites·11 claims
- 1093US9477906B2Classification generation method using combination of mini-classifiers with regularization and uses thereofBIODESIX INC·Filed 2014·Granted Oct 25, 2016·21 cites·39 claims
- 1193US8119417B2Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Feb 21, 2012·8 cites·4 claims
- 1293US8119418B2Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Feb 21, 2012·8 cites·4 claims
- 1392US10217620B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2018·Granted Feb 26, 2019·6 cites·10 claims
- 1492US9279798B2Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereofBIODESIX INC·Filed 2013·Granted Mar 8, 2016·18 cites·21 claims
- 1592US8586379B2Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Nov 19, 2013·6 cites·4 claims
- 1692US8586380B2Monitoring treatment of head and neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesROEDER HEINRICH·Filed 2011·Granted Nov 19, 2013·6 cites·4 claims
- 1792US8097469B2Method and system for determining whether a drug will be effective on a patient with a diseaseROEDER HEINRICH·Filed 2010·Granted Jan 17, 2012·15 cites·17 claims
- 1892US7858390B2Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·26 cites·7 claims
- 1991US11894147B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2022·Granted Feb 6, 2024·2 cites·7 claims
- 2091US10037874B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2015·Granted Jul 31, 2018·6 cites·9 claims
- 2190US11594403B1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2018·Granted Feb 28, 2023·4 cites·11 claims
- 2290US11476003B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2021·Granted Oct 18, 2022·3 cites·10 claims
- 2390US8467988B1Method and system for validation of mass spectrometer machine performanceROEDER JOANNA·Filed 2013·Granted Jun 18, 2013·18 cites·20 claims
- 2490US7867775B2Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Jan 11, 2011·21 cites·5 claims
- 2589US9606101B2Deep MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereofBIODESIX INC·Filed 2015·Granted Mar 28, 2017·7 cites·6 claims
- 2689US9211314B2Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2014·Granted Dec 15, 2015·6 cites·30 claims
- 2789US8914238B2Method for predicting breast cancer patient response to endocrine therapyRÖDER JOANNA·Filed 2012·Granted Dec 16, 2014·12 cites·7 claims
- 2887US10713590B2Bagged filtering method for selection and deselection of features for classificationBIODESIX INC·Filed 2016·Granted Jul 14, 2020·5 cites·24 claims
- 2987US9254120B2Method for predicting breast cancer patient response to combination therapyBIODESIX INC·Filed 2013·Granted Feb 9, 2016·5 cites·8 claims
- 3086US9152758B2Method and system for determining whether a drug will be effective on a patient with a diseaseRÖDER HEINRICH·Filed 2011·Granted Oct 6, 2015·7 cites·2 claims
- 3185US10950348B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2018·Granted Mar 16, 2021·2 cites·11 claims
- 3285US9824182B2Method and system for determining whether a drug will be effective on a patient with a diseaseRÖDER HEINRICH·Filed 2010·Granted Nov 21, 2017·7 cites·1 claims
- 3382US2025336497A1Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3481US8024282B2Method for reliable classification of samples in clinical diagnostics using an improved method of classificationBIODESIX INC·Filed 2008·Granted Sep 20, 2011·11 cites·34 claims
- 3579US11150238B2Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2018·Granted Oct 19, 2021·1 cites·8 claims
- 3677US12094587B2Apparatus and method for identification of primary immune resistance in cancer patientsBIODESIX INC·Filed 2019·Granted Sep 17, 2024·1 cites·19 claims
- 3775US11710539B2Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapyBIODESIX INC·Filed 2017·Granted Jul 25, 2023·1 cites·4 claims
- 3875US9653272B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2013·Granted May 16, 2017·2 cites·72 claims
- 3974US11621057B2Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapyBIODESIX INC·Filed 2017·Granted Apr 4, 2023·1 cites·11 claims
- 4074US10593529B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2017·Granted Mar 17, 2020·1 cites·15 claims
- 4174US2023197426A1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2023·Application pending·0 cites
- 4270US12230398B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2020·Granted Feb 18, 2025·0 cites·7 claims
- 4369US2022026416A1Method for identification of cancer patients with durable benefit from immunotehrapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2021·Application pending·0 cites
- 4464US2021369775A1Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4560US2012191370A1Method and system for determining whether a drug will be effective on a patient with a diseaseRODER HEINRICH·Filed 2012·Application pending·0 cites
- 4659US2014200825A1Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2014·Application pending·0 cites
- 4758US2004102906A1Image processing of mass spectrometry data for using at multiple resolutionsEFECKTA TECHNOLOGIES CORP·Filed 2003·Application pending·0 cites
- 4857US2014284468A1Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samplesBIODESIX INC·Filed 2014·Application pending·0 cites
- 4955US2016019342A1Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2015·Application pending·0 cites
- 5052US10436795B2Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a proteinINSTITUTE FOR CANCER RES·Filed 2017·Granted Oct 8, 2019·0 cites·15 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Heinrich Röder files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →